1:14 New DNA Test Detects Mutations in Urine of Bladder Cancer Patients Over a Decade Before Diagnosis Bladder Cancer Content Hub For diagnosis 1 year after sample collection, the test detected mutations in 90% of patients.
1:15 Bladder Sparing Trimodal Therapy Evaluated for Clinical Efficacy in Retrospective Study Bladder Cancer Content Hub The recurrence rate for cystectomy was 38% compared to 59% for TMT.
1:10 Genomic Test May Predict Which Patients Would Benefit Most from Checkpoint Inhibition Bladder Cancer Content Hub Bladder, lung, and skin cancer patients frequently showed evidence of high tumor mutational burden.
:50 Updated Guidelines for Treatment of Non-Metastatic MBIC to be Presented at AUA Meeting Bladder Cancer Content Hub The AUA has teamed up with ASCO, ASTRO, and SUO to provide new guidelines for non-metastatic MBIC treatment.
1:06 Pelvic Radiotherapy Provides Long-Term Palliation In Patients With Bladder and Prostate Cancer Bladder Cancer Content Hub A recent study investigated utilizing palliative pelvic radiotherapy for metastatic bladder or prostate cancer patients.
:59 Multiple Clinical Trials of Immunotherapies for Recurrent and Metastatic Cancers Are Reaching Maturation Bladder Cancer Content Hub There are currently a large number of ongoing trials examining immunotherapies for bladder, kidney, prostate, and renal cancers.
1:12 Phase II Results Support Inclusion of Checkpoint Inhibitors in Bladder Cancer Treatment Guidelines Bladder Cancer Content Hub NCCN to add two new checkpoint inhibitors to bladder cancer treatment guidelines.
1:21 Experienced Oncologists Are More Likely to Utilize Adjuvant Radiation Therapy in MIBC Bladder Cancer Content Hub A new study reveals reasons why some oncologists use adjuvant radiation therapy (ART) when treating MIBC.
1:09 Accurate Staging of Bladder Cancer Proves Crucial for Improving Disease Treatment Bladder Cancer Content Hub Muscle-invasive bladder cancer (MIBC) is considered to be T2 stage due to tumor invasion into the muscle wall.
1:13 Super-Responders vs. Hyper-Progression with Immunotherapy Bladder Cancer Content Hub The trial revealed a linear correlation between higher tumor burden and anti-PD1 and anti-programmed death ligand (PD-L1) checkpoint inhibitors, explained as the immune system responding to reactivation.
